| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4-Hydrazinobenzoic acid targets the human p53 and p16 tumor suppressor genes. These genes play a crucial role in controlling cell division and preventing tumor formation. The compound prevents the formation of hydrogen bonds between nucleotides in DNA. It has been shown to inhibit the growth of human breast cancer cells by reactivating the tumor suppressor genes p21 and Rb1, which are responsible for regulating cell cycle progression.
|
|---|---|
| ln Vitro |
In vitro, 4-hydrazinobenzoic acid derivatives have been shown to inhibit the proliferation of cancer cells such as HCT-116 and MCF-7 by inducing apoptosis. The synthesized derivatives have been tested for their antimicrobial activity against various pathogenic microorganisms. The compound exhibits antioxidant properties, cytotoxic effects against cancer cells, and potential genotoxicity.
|
| ln Vivo |
In vivo data for 4-hydrazinobenzoic acid as a therapeutic agent are limited. The compound has been shown to inhibit the growth of human breast cancer cells by reactivating tumor suppressor genes. However, specific in vivo efficacy and pharmacokinetic data for the parent compound are not well-documented. Its in vivo relevance is primarily indirect, through the biological activities of its derivatives.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, 4-hydrazinobenzoic acid can be evaluated for its interaction with p53 and p16 tumor suppressor proteins. Standard protocols involve incubating the compound with recombinant proteins and measuring binding affinity using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The compound's ability to prevent hydrogen bond formation between DNA nucleotides can be assessed using DNA binding assays.
|
| Cell Assay |
For in vitro cell-based experiments, 4-hydrazinobenzoic acid is evaluated for anticancer activity against cancer cell lines such as HCT-116 and MCF-7. Cells are seeded in 96-well plates and treated with the compound at various concentrations (typically 0.1-100 µM) for 24-72 hours. Cell viability is assessed using MTT or resazurin-based assays. Apoptosis is measured using flow cytometry with Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies using 4-hydrazinobenzoic acid are limited. For potential anticancer candidates derived from this scaffold, efficacy studies would typically be performed in mouse xenograft models of cancer. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of tumor volume or survival as endpoints. Specific protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-hydrazinobenzoic acid are not extensively characterized. The compound has a molecular weight of 152.15 g/mol, which is favorable for oral bioavailability. The hydrazine moiety may influence metabolic stability and reactivity. As a small, polar molecule, it is expected to have reasonable membrane permeability. Empirical pharmacokinetic data are not available in the public literature.
|
| Toxicity/Toxicokinetics |
4-Hydrazinobenzoic acid is a research chemical and should be handled with appropriate laboratory safety precautions. As a hydrazine derivative, it may be toxic and should be handled with extreme care. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
According to reports, button mushrooms contain 4-hydrazinobenzoic acid, and there is relevant data.
4-Hydrazinobenzoic acid (p-Hydrazinobenzoic acid, CAS 619-67-0) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for pharmaceutical intermediates and bioactive scaffolds. The compound targets p53 and p16 tumor suppressor genes and shows anticancer activity. No clinical trials or approved indications exist. |
| Molecular Formula |
C7H8N2O2
|
|---|---|
| Molecular Weight |
152.15
|
| Exact Mass |
152.058
|
| CAS # |
619-67-0
|
| Related CAS # |
24589-77-3 (mono-hydrochloride)
|
| PubChem CID |
12089
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
377.2±25.0 °C at 760 mmHg
|
| Melting Point |
218 °C (dec.)(lit.)
|
| Flash Point |
181.9±23.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.694
|
| LogP |
1.36
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
141
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)C1=CC=C(NN)C=C1
|
| InChi Key |
PCNFLKVWBDNNOW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8N2O2/c8-9-6-3-1-5(2-4-6)7(10)11/h1-4,9H,8H2,(H,10,11)
|
| Chemical Name |
4-hydrazinylbenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5725 mL | 32.8623 mL | 65.7246 mL | |
| 5 mM | 1.3145 mL | 6.5725 mL | 13.1449 mL | |
| 10 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
